{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': '19 Presidential Way',
 'address2': '2nd Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 27,
 'askSize': 1100,
 'averageDailyVolume10Day': 126412,
 'averageVolume': 260728,
 'averageVolume10days': 126412,
 'beta': None,
 'beta3Year': None,
 'bid': 21.05,
 'bidSize': 1100,
 'bookValue': -25.04,
 'category': None,
 'circulatingSupply': None,
 'city': 'Woburn',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 22.95,
 'dayLow': 21.9607,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -25.239,
 'enterpriseToRevenue': 13.629,
 'enterpriseValue': 493502368,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 21.724571,
 'fiftyTwoWeekHigh': 28.78,
 'fiftyTwoWeekLow': 11.17,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 23302929,
 'forwardEps': -0.43,
 'forwardPE': -52.279068,
 'fromCurrency': None,
 'fullTimeEmployees': 43,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.16073999,
 'heldPercentInstitutions': 0.44417,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/frequencytx.com',
 'longBusinessSummary': 'Frequency Therapeutics, Inc., a clinical-stage '
                        'biotechnology company, focuses on harnessing the '
                        "body's innate biology to repair or reverse damage "
                        'caused by a broad range of degenerative diseases. Its '
                        'Progenitor Cell Activation approach, uses '
                        'combinations of small molecules to activate '
                        'progenitor cells within the body to create functional '
                        "tissue. The company's lead product candidate is "
                        'FX-322, which is in phase 2a clinical trial to treat '
                        'the underlying cause of sensorineural hearing loss. '
                        'It is also developing medicines for patients across a '
                        'range of degenerative conditions, including multiple '
                        'sclerosis, and diseases of the muscle, '
                        'gastrointestinal tract, skin, and bone. Frequency '
                        'Therapeutics, Inc. has a licencse and collaboration '
                        'agreement with Astellas Pharma Inc. for the '
                        'development and commercialization of FX-322. '
                        'Frequency Therapeutics, Inc. was founded in 2014 and '
                        'is headquartered in Woburn, Massachusetts.',
 'longName': 'Frequency Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 750004736,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_416409020',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -18887000,
 'nextFiscalYearEnd': 1640908800,
 'open': 22.53,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '866 389 1970',
 'previousClose': 22.78,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 20.712069,
 'profitMargins': -0.49247003,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 22.95,
 'regularMarketDayLow': 21.9607,
 'regularMarketOpen': 22.53,
 'regularMarketPreviousClose': 22.78,
 'regularMarketPrice': 22.53,
 'regularMarketVolume': 74404,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 33363200,
 'sharesPercentSharesOut': 0.1368,
 'sharesShort': 4241746,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2584948,
 'shortName': 'Frequency Therapeutics, Inc.',
 'shortPercentOfFloat': 0.152,
 'shortRatio': 9.05,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'FREQ',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -10.293,
 'twoHundredDayAverage': 20.158705,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '982d003c-979c-3ca8-8fba-657032c9b301',
 'volume': 74404,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.frequencytx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '01801'}